Harris 2004.

Methods	Study design: parallel RCT Study duration: NS Study follow‐up: 12 weeks
Participants	Country: USA Setting: multicentre (2 centres) Medically stable patients with serum calcium levels corrected for albumin concentration ≥ 8.4 mg/dL; serum phosphorous levels ≥ 3.0 mg/dL Number: treatment group (17); control group (5) Mean age ± SD (years): treatment group (48.5 ± 10.4); control group (48 ± 13.1) Sex (M/F): treatment group (14/3); control group (4/1) Exclusion criteria: NS
Interventions	Treatment group Cinacalcet: 25 to 300 mg/d Duration: 12 weeks Control group Placebo Co‐interventions Treatment group: vitamin D (71%); phosphate binders (100%) Control group: vitamin D (60%); phosphate binders (80%)
Outcomes	Pharmacodynamic data at doses > 100 mg Adverse effects
Notes	ITT: no Funding: "From Pharmacokinetics and Drug Metabolism, Early Development, and Biostatistics, Amgen Inc, Thousand Oaks, CA; Orlando Clinical Research Center, Orlando, FL; and Clinical Research Center, New Orleans, LA" Not included in meta‐analyses
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NS
Allocation concealment (selection bias)	Unclear risk	NS
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	NS
Incomplete outcome data (attrition bias) All outcomes	High risk	Loss to follow‐up 59.1% of patients
Selective reporting (reporting bias)	High risk	Not reported systematically (end of treatment calcium, phosphorous, PTH and adverse events)
Other bias	High risk	Sponsor on authorship